A recent clinical trial of an immune-modulatory vaccine activates IDO/PD-L1 specific T cells, targets cancer cells by IDO- and PD-L1-specific CD8+ T cells, and releases pro-inflammatory cytokines by CD4+ T cells. This evidence concerns the gene CD274 and cancer.